MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
13.18
+0.05
+0.38%
Pre Market: 12.91 -0.27 -2.05% 04:00 05/15 EDT
OPEN
13.19
PREV CLOSE
13.13
HIGH
13.35
LOW
12.96
VOLUME
7
TURNOVER
0
52 WEEK HIGH
20.76
52 WEEK LOW
8.50
MARKET CAP
2.11B
P/E (TTM)
-40.2566
1D
5D
1M
3M
1Y
5Y
1D
Adaptive Biotechnologies Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 2d ago
Adaptive Biotechnologies Price Target Cut to $18.00/Share From $21.00 by Morgan Stanley
Dow Jones · 2d ago
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18
Benzinga · 2d ago
Adaptive Biotechnologies price target lowered to $18 from $21 at Morgan Stanley
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
TipRanks · 2d ago
Cathie Wood's weekly recap: buys TEM, WGS, and CRWV; sells AMD and RKLB
Seeking Alpha · 4d ago
Weekly Report: what happened at ADPT last week (0504-0508)?
Weekly Report · 4d ago
A Look At Adaptive Biotechnologies (ADPT) Valuation After Strong Q1 MRD Growth And Raised Full Year Guidance
Simply Wall St · 4d ago
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Webull offers Adaptive Biotechnologies Corp stock information, including NASDAQ: ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.